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Objective: To determine whether the mRNA concentrations of inflammation response genes in isolated adipocytes and in
cultured preadipocytes are related to adipocyte size and in vivo insulin action in obese individuals.
Design: Cross-sectional inpatient study.
Subjects: Obese Pima Indians with normal glucose tolerance.
Measurements: Adipocyte diameter (by microscope technique; n¼29), expression of candidate genes (by quantitative real-
time PCR) in freshly isolated adipocytes (monocyte chemoattractant protein (MCP) 1 and MCP2, macrophage inflammatory
protein (MIP) 1a, MIP1b and MIP2, macrophage migration inhibitory factor (MIF), tumor necrosis factor a, interleukin (IL) 6 and
IL8; n¼22) and cultured preadipocytes (MCP1, MIP1a, MIF, IL6 and matrix metalloproteinase 2; n¼33) from subcutaneous
abdominal adipose tissue (by aspiration biopsy, n¼34), body fat by dual-energy X-ray absorptiometry, glucose tolerance
by 75g oral glucose tolerance test and insulin action by euglycemic-hyperinsulinemic clamp (insulin infusion rate
40mUm2min1) (all n¼ 34).
Results: MIF was the only gene whose expression in both freshly isolated adipocytes and cultured preadipocytes was positively
associated with adipocytes diameter and negatively associated with peripheral and hepatic insulin action (all Po0.05). In
multivariate analysis, the association between adipocyteMIFmRNA concentrations and adipocytes diameter was independent of
the percentage of body fat (P¼0.03), whereas adipocyteMIFmRNA concentrations, but not adipocyte diameter, independently
predicted peripheral insulin action. The mRNA expression concentrations of theMIF gene in adipocytes were not associated with
plasma concentrations of MIF, but were negatively associated with plasma adiponectin concentrations (P¼ 0.004). In
multivariate analysis, adipocyte MIF RNA concentrations (P¼ 0.03) but not plasma adiponectin concentrations (P¼ 0.4)
remained a significant predictor of insulin action.
Conclusions: Increased expression of MIF gene in adipose cells may be an important link between obesity characterized by
enlarged adipocytes and insulin resistance in normal glucose tolerant people.
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Introduction
Obesity and insulin resistance are associated with chronic
subclinical inflammation.1,2 More than a decade ago it became
evident that adipose tissue itself may have an active role in
the obesity-related inflammation through its production of
proinflammatory cytokines.3,4 Further studies have shown
that inflammation-related genes are the most prominently
expressed genes in white adipose tissue in animal models of
obesity.5–7 Moreover, increased expression of inflammatory
cytokines in adipose tissue in these animals precedes
hyperinsulinemia and overt hyperglycemia6 indicating
that increased adipose tissue inflammation may have
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a pathophysiological role in metabolic complications of
obesity.8
More detailed studies of different cell types within the
adipose tissue have shown that many of those cytokines are
predominantly produced by cells of non-adipose lineage,9,10
including macrophages,11 that increasingly infiltrate adipose
tissue of obese individuals.5,6 However, inflammation-
related genes are still among the most overexpressed genes
in cells of adipose lineage such as freshly isolated matured
adipocytes12 and cultured preadipocytes13 from obese indi-
viduals. It has been hypothesized that under positive-energy
balance, as adipose cells increase in size, they start to
produce molecules with chemoattracting and activating
effects on monocytes/macrophages.8 In fact, macrophage
content in human subcutaneous adipose tissue is positively
related to adipocyte size5 and large adipocytes produce
higher concentrations of chemokines than small ones.14
It has been shown that subjects with enlarged subcuta-
neous adipocytes are, on average, more insulin-resistant and
at higher risk for developing diabetes mellitus than those
with a similar degree of adiposity but relatively smaller
adipocytes.15,16 Given that many individuals who are very
obese are still relatively insulin sensitive,17,18 we hypo-
thesized that increased expression of inflammation-related
genes in subcutaneous abdominal adipocytes in obese
subjects would be more specifically related to adipocyte size
and predict in vivo insulin action. Candidate genes were
mainly selected from genes known to be expressed at higher
levels in adipocytes and/or cultured preadipocytes of obese
Pima Indians compared with lean controls.12,13 In adipo-
cytes, we determined the expression levels of: monocyte
chemoattractant protein (MCP) 1, macrophage inflamma-
tory protein (MIP) 1a,MIP 1b,MIP 2a, macrophage migration
inhibitory factor (MIF), tumor necrosis factor a (TNFa) and
interleukin-8 (IL8). In addition, we included interleukin 6
(IL6) because of its possible role in the development of
insulin resistance and MCP 2 because of its potential role in
attracting macrophages into adipose tissue. In cultured
preadipocytes we studied the expression levels of MCP1,
MIP1a, MIF, IL6 and matrix metalloproteinase 2 (MMP2).
Methods
Subjects in this study were at least half Pima (or closely
related Tohono O’Odham) Indians from the Gila River
Indian Community. All subjects were between 18 and
45 years of age, obese (BMIX30 kgm2), with normal plasma
fasting and 2-h glucose concentration values according to
a 75-g oral glucose tolerance test (OGTT, World Health
Organization 1999 criteria;o6.1 ando7.8mmol l1, respec-
tively), and nonsmokers at the time of the study. Acute and
chronic diseases were excluded on the basis of medical
history, physical examination and routine laboratory tests.
Subjects with evidence of serious medical conditions
(including autoimmune, cerebrovascular and ischemic heart
disease) or taking any medications, including contraceptives,
were excluded. The protocol was approved by the Institu-
tional Review Board of the National Institute of Diabetes and
Digestive and Kidney Diseases, and all subjects provided
written informed consent before participation. To minimize
changes in glucose and adipose metabolism resulting from
ovarian hormonal effects, the female participants were
studied during the follicular phase (days 0 through 14) of
the menstrual cycle.
All subjects were admitted to the National Institutes of
Health Clinical Research Unit in Phoenix, AZ, USA and were
placed on a weight-maintaining diet (containing 50% of
calories as carbohydrates, 30% as fat and 20% as protein) for
2–3 days before clinical testing. Body composition was
measured by dual-energy X-ray absorptiometry using a total
body scanner (DPX-L; Lunar Radiation, Madison, WI, USA).
At least 3 days after admission and after a 12-h overnight
fast, subjects underwent OGTT to exclude impaired glucose
tolerance or diabetes. Plasma glucose concentrations were
determined by the glucose oxidase method (Beckman
Instruments, Fullerton, CA, USA) and plasma insulin con-
centrations by an automated immunoassay (Access;
Beckman Instruments). Plasma MIF was measured using a
human specific sandwich enzyme-linked immunosorbent
assay from R&D Systems (Minneapolis, MN, USA). Serum
samples were diluted 1:10 for analysis and all samples were
run in duplicate in the same assay. Total plasma adipo-
nectin concentration was determined using a validated
sandwich enzyme-linked immunosorbent assay employing
an adiponectin-specific antibody (intra-assay and inter-
assay coefficients of variation 3.3 and 7.4%, respectively).
Luminex bead array (LINCOplex, Linco Research Inc.,
St Charles, MO, USA) multianalyte detection system was
used to determine serum concentrations of 13 cytokines
(IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13,
IFN-g, GM-CSF and TNF-a).
Insulin action was assessed at physiological insulin con-
centrations during a hyperinsulinemic-euglycemic glucose
clamp.19 Briefly, after an overnight fast a primed (30 mCi)
continuous (0.3 mCimin1) 3-[3H] glucose infusion was
started to determine endogenous glucose production (EGP).
Two hours after starting the isotope infusion, a primed
continuous intravenous insulin infusion was administered
for 100min at a constant rate of 40mU per m2 body surface
area per minute. Blood samples for measurement of 3-[3H]
glucose-specific activity were collected at the end of the basal
period and every 10min during the final 40min of insulin
infusion. Under basal conditions, EGP was calculated as the
3-[3H] glucose infusion rate divided by the steady-state
plasma 3-[3H] glucose-specific activity. During the insulin
clamp, EGP was calculated from Steele’s equation20 and was
used as a surrogate for insulin sensitivity in the liver. The rate
of total insulin-stimulated glucose disposal was calculated
for the last 40min of the insulin infusion and was corrected
for the rate of EGP. Individual variation in plasma glucose
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and insulin concentrations during the clamp were taken into
account in the calculation of the insulin-mediated glucose
disposal (M).19,21 All measurements derived from the clamp
were normalized to estimated metabolic body size (EMBS, or
fat-free massþ 17.7 kg) to account for the fact that the
intercept of the relationship between fat-free mass and
resting metabolic rate is not zero.22
Fat biopsies were obtained after a 12-h overnight fast,
between 0830 and 1000 hours. Subcutaneous abdominal
adipose tissue was removed from the periumbilical region by
percutaneous needle biopsy under local anesthesia (lidocaine
1%). The biopsy specimen was placed on a sterile nylon
mesh, rinsed with sterile 0.9% NaCl solution and cleaned of
visible connective tissue and blood vessels in Hank’s Buffered
Saline Solution (HBSS) supplemented with 5.5mM glucose.
Isolation of the adipocytes and stromal vascular fraction
containing preadipocytes (and other cells) was performed
according to a previously described method.12,13 Briefly,
adipose tissue was digested in HBSS buffer containing
5.5mM glucose, 5% fatty acid-free BSA (Introgen/Serologicals,
Norcross, GA, USA) and 3.3mgml1 type I collagenase
(Worthington Biochemical Corp., Lakewood, NJ, USA) for
30min in a 37 1C water bath. The digestion mixture was
passed through a sterile 230 mm stainless steel tissue sieve
(Thermo EC, Holbrook, NY, USA), and the adipocytes were
allowed to float by gravity and collected for adipocyte size
measurement and RNA isolation.
The preadipocyte-containing infranatant was collected
into a separate tube and washed several times with HBSS.
The stromal vascular fraction cells (hereafter referred to
as preadipocytes) were resuspended in standard medium
consisting of Medium 199 (Life Technologies, Grand Island,
NY, USA) supplemented with 1mgml1 amphotericin B,
100Uml1 penicillin G sodium, 100mgml1 streptomycin
sulfate, 2mmol l1 Glutamax-1 and 10% heat-inactivated
FBS (Life Technologies). The cell suspension was strained
through a sterile 25-mm stainless steel tissue sieve (Thermo
EC). The filtrate was transferred to a T75 culture flask and
maintained in an incubator at 37 1C in 5% CO2. Cells were
allowed to attach and, the next day, floating red blood cells
were removed by aspiration and the culture medium was
replenished. At subconfluency, the cultured cells were
trypsinised and plated at a concentration of approximately
1.5106 cells per 15-cm dish for RNA extraction, which was
carried out approximately 14 days after the biopsy date.
Media was changed every 2–3 days throughout the culturing
period. Preadipocyte culturing was completed in 33 of 34
samples obtained.
RNA from adipocytes and cultured preadipocytes was
extracted using RNeasy Mini Kit from Qiagen (Valencia,
CA, USA). During the extraction, RNA was treated with
RNAse-free DNAse (Qiagen) according to the manufacturer’s
instruction. RNA extracts were stored at 70 1C until shipped
on dry ice for analyses to Phoenix VA Health Care System
(adipocytes) and Pennington Biomedical Research Center
(preadipocytes).
Twenty-two of the 34 volunteers had sufficient amount of
adipocyte RNA for the assay. The RNA was used to synthesize
cDNA using iScript cDNA Synthesis Kit (BioRad, Hercules,
CA, USA). Quantitative real-time PCR (QRT-PCR) was carried
out using SYBR Green chemistry (iQ SYBR Green Supermix;
BioRad) and analyzed by an iCycler iQ Real-Time Detection
System (BioRad) following the manufacturer’s recommen-
dation. Successful cDNA synthesis was verified by PCR
amplification of b2-microglobulin transcript using forward
primer 50-TGTCTTTCAGCAAGGACTGGTC-30 and reverse
primer 50-TGATGCTGCTTACATGTCTCGAT-30. Quantifica-
tion of candidate genes mRNA concentrations was carried
out using gene-specific primers (see Supplementary Table 1
for primer sequences). Each sample was run in duplicate and
the mean value was used to calculate the transcript level.
A standard curve for each primer-probe set was generated by
serial dilution of cDNA from a healthy subject done in
triplicate. Reactions without template were included as
negative controls. The reaction was carried out at 95 1C for
3min and followed by 40 cycles of amplification (94 1C for
20 s, 60 1C for 40 s). The reaction was further subjected to 66
cycles of 0.5 1C increments (10 s each) beginning at 62 1C for
melting curve analysis to confirm the specificity of amplifi-
cation products. The mRNA concentrations of candidate
genes were normalized to the geometric mean of those for
human cyclophilin, TATA box-binding protein and 18 s
ribosomal RNA. For the preadipocyte gene expression work,
QRT-PCRs were performed as previously described23 on an
ABI Prism 7700 Sequence Detection System (Perkin-Elmer
Applied Biosystems, Foster City, CA, USA). The mRNA
concentrations of candidate genes were normalized to those
for human cyclophilin. Each sample was run in duplicate
and mean values were used for the expression of each gene
(primer sequences in Supplementary Table 1). Preadipocyte
gene expression analysis was performed on samples from
33 volunteers.
An aliquot of the adipocyte suspension was used for cell
size measurement by microscope technique. Briefly, packed
adipocytes were mixed at a ratio of 1:2 with Medium 199
(Life Technologies) containing 1% heat-inactivated FBS (Life
Technologies), 1% BSA (Introgen/Serologicals), and 50nM
adenosine (Sigma-Aldrich, St Louis, MO, USA) on a
chambered slide covered with a cover slip. Representative
pictures of the adipocytes were taken using a Polaroid
Microcam (Polaroid) on an inverted microscope (Eclipse
TE200), and the adipocyte cell perimeters on scanned images
were measured using Scion Image (Scion, Frederick, MD,
USA) by three independent readers. The inter-reader varia-
bility was 4.7%. The mean cell diameter from samples was
calculated from the mean cell perimeter of the three
readings. As recommended,24 only samples with at least
100 sized cells (n¼29) were included in further analyses.
Statistical analyses were performed using the software
of the SAS Institute (Cary, NC, USA). Each gene mRNA
concentration was normalized by taking the residuals after
linear regression to the reference gene(s). Depending on the
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data distribution, Student’s t-test or Mann–Whitney test
was used for comparison between men and women, and
Pearson-r or Spearman-r correlation was used to test for
simple or partial correlations between the variables. General
linear regression analysis was used to test for independent
determinants of the outcomes after adjusting for confounders.
Non-normally distributed data were logarithmically trans-
formed to approximate normal distribution before being
analyzed in the multivariate analysis. P-values less than 0.05
were considered to be statistically significant.
Results
Anthropometric and metabolic characteristics of the study
population are presented in Table 1. Women had on average
higher percentage of body fat (BF, Po0.0001) and larger
adipocytes (P¼0.0002) compared with men (Table 1). There-
fore, gender was considered as a confounder in all analyses
involving BF and adipocyte diameter. Metabolic character-
istics of the subgroup of subjects who had available gene
expression data in isolated adipocytes were similar. The
expression levels of the candidate genes were not signifi-
cantly different between men and women (data not shown).
The expression levels of macrophage migration inhibitory
factor (MIF) gene in cultured preadipocyte was the only
one of the adipocyte or preadipocyte genes studied that
was significantly associated (positively) with adiposity (BF,
P¼0.01, Table 2). A positive correlation was found between
mean adipocyte diameter and expression levels of MIF in
both adipocytes and preadipocytes (both P¼0.02, Table 2
and Figure 1). On the other hand, adipocyte diameter was
negatively associated with the expression levels of macro-
phage inflammatory protein 1a (MIP1a) in preadipocytes
(P¼0.02, Table 2). After adjustment for sex and BF, only
the MIF expression in adipocytes was independently related
to adipocyte diameter (P¼0.03), whereas neither adipo-
cyte diameter nor BF were significant predictors of pre-
adipocyte MIF mRNA concentrations (P¼0.09 and P¼0.08,
respectively).
As shown in Table 2, MIF was the only gene whose
increased mRNA expression in isolated adipocytes was
significantly associated with high fasting and 2-h plasma
concentrations of glucose (Po0.05 and P¼0.02, respec-
tively) and insulin (P¼0.004 and P¼0.0002, respectively),
and with reduced insulin action at the periphery
(M, P¼0.02) and liver (EGPins, Po0.0001, Figure 2). Simi-
larly, increased expression level of MIF mRNA in cultured
preadipocytes was the only significant correlate of high
fasting and 2-h plasma concentrations of glucose (P¼0.002
and P¼0.02, respectively) and insulin (P¼0.003 and
P¼0.03, respectively) (Table 2). M and EGPins was positively
correlated with MIF mRNA concentrations in cultured
Table 1 Anthropometric and metabolic characteristics of the study population
Variable All Men Women
N 34 18 16
Age (years) 24 (23, 32) 24 (23, 28) 25 (20, 34)
BMI (kgm2) 36 (5) 36 (4) 36 (5)
Body fat (%) 36 (5) 33 (3) 39 (4)c
Adipocyte diameter (mm)a 67 (9) 62 (8) 73 (5)b
Fasting plasma glucose (mmol l1) 4.93 (0.50) 4.90 (0.53) 4.95 (0.48)
2 h plasma glucose (mmol l1) 6.25 (5.17, 7.0) 6.25 (4.39, 7.0) 6.31 (5.44, 6.94)
Fasting plasma insulin (mUml1) 11 (6) 11 (7) 11 (5)
2-h plasma insulin (mUml1) 58 (27, 84) 43 (17, 146) 63 (40, 83)
M (mmol kgEMBS
1 min1) 14.3 (12.7, 17.4) 14 (12.4, 17.4) 14.7 (12.8, 17.5)
EGPfast (mmol kgEMBS
1 min1) 9.8 (2.5) 9.4 (1.7) 10.2 (1.1)
EGPins (mmol kgEMBS
1 min1) 1.7 (0, 3.5) 1.7 (0, 3.2) 1.7 (1.4, 3.8)
Expressed as means (s.d.) or median (lower quartile, upper quartile); data availability: a29 (13F); bPo0.001, cPo0.0001, sex comparison; M, insulin-mediated
glucose disposal; EGP, endogenous glucose production; EMBS, estimated metabolic body size (fat-free mass+17.7).
Table 2 Correlation of clinical characteristics with the expression levels of
adipocyte and preadipocyte candidate genes
Gene BFb ADb FPG 2hPGa FPI 2hPI Ma EGPfast EGP
A
ins
Adipocytes: n¼22
MCP1 0.22 0.24 0.17 0.15 0.14 0.11 0.11 0.27 0.1
MCP2 0.19 0.26 0.22 0.26 0.15 0.04 0.19 0.38 0.16
MIF 0.14 0.53c 0.43c 0.49c 0.59d 0.72e 0.50c 0.21 0.75f
MIP1a 0.20 0.27 0.15 0.02 0.24 0.05 0.14 0.02 0.15
MIP1b 0.16 0.31 0.17 0.02 0.21 0.04 0.10 0.05 0.18
MIP2 0.32 0.43 0.05 0.07 0.35 0.09 0.09 0.20 0.12
IL6 0.20 0.41 0.05 0.11 0.19 0.09 0.06 0.35 0.09
IL8 0.35 0.39 0.03 0.08 0.41 0.17 0.16 0.23 0.07
TNFa 0.25 0.18 0.24 0.05 0.07 0.24 0.13 0.10 0.20
Preadipocytes: n¼33
MCP1 0.09 0.15 0.02 0.06 0.14 0.10 0.02 0.15 0.02
MIF 0.44c 0.44c 0.53d 0.34c 0.50d 0.38c 0.40c 0.07 0.41c
MIP1a 0.04 0.46c 0.01 0.13 0.29 0.20 0.01 0.20 0.03
IL6 0.12 0.24 0.04 0.10 0.002 0.02 0.09 0.18 0.08
MMP2 0.08 0.24 0.18 0.17 0.18 0.19 0.14 0.13 0.13
Pearson or aSpearman, simple or bpartial (sex) correlation coefficients;
cPo0.05, dPo0.01, ePo0.001, fPo0.0001; AD, adipocyte diameter; BF,
body fat; FPG, fasting glucose; 2hPG, 2 h glucose; FPI, fasting insulin; M,
glucose disposal; EGP, endogenous glucose production; MCP, monocyte
chemoattractant protein; MIP, macrophage inflammatory protein; MIF,
macrophage migration inhibitory factor; TNF, tumor necrosis factor; IL,
interleukin; MMP, matrix metalloproteinase.
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preadipocytes as well (P¼ 0.02 and P¼0.01, respectively;
Table 2, Figure 2).
Sex-adjusted adipocyte diameter was significantly
associated with M (log10, b¼0.009, s.e.¼0.004, P¼0.02)
before but not after (P¼0.9) further adjustment forMIF gene
expression level in adipocytes. The expression of MIF in
adipocytes was the only significant predictor of M in this
model (b¼0.36, s.e.¼0.14, P¼0.02). The effect of pre-
adipocyte MIF gene expression on M disappeared (P¼0.9)
after adjustment for adipocyte diameter. EGPins was not
associated with adipocyte diameter (P¼0.7).
Finally, we tested whether differences in circulatory factors
may explain the relationships between the expression of the
MIF gene in adipose cells and insulin action. Plasma
concentration of MIF neither correlated with the mRNA
expression levels of MIF gene in adipocytes or preadipocytes
(Figure 3) nor was a significant predictor of M (r¼0.19,
P¼0.3) or EGPins (r¼0.07, P¼0.7). Adiponectin was the
only adipokine whose circulatory concentration was signifi-
cantly associated with both the expression levels ofMIF gene
in adipocytes (but not in preadipocytes, Figure 3) and insulin
action (M, r¼0.46, P¼0.006; EGPins, r¼0.57, P¼0.0004).
In a multivariate model, adipocyte MIF expression
(b¼0.32, s.e.¼0.13, P¼0.03) but not plasma adiponectin
(P¼0.4) predicted M, whereas neither of the two variables
predicted EGPins (P¼ 0.6 and P¼0.15, respectively).
Discussion
The results of this study demonstrate that the mean size of
adipocytes from abdominal subcutaneous adipose tissue was
positively associated with the expression levels of the gene
for macrophage migration inhibitory factor (MIF) in both
freshly isolated adipocytes and cultured preadipocytes of
subcutaneous adipose tissue from obese Pima Indians. In
addition, increased levels of MIF mRNA from both cell types
were associated with higher fasting and 2-h plasma glucose
and insulin concentrations, and reduced peripheral and
hepatic insulin action.
Adipocytes produce proteins that impact distant tissues,
such as liver, skeletal muscle and brain, as well as proteins
that affect either neighboring adipocytes or other local cell
types within adipose tissue.25 Translational and proteomic
studies have shown that adipocytes produce factors that
attract macrophages into adipose tissue.12,26 The production
of these signals may change with the expansion of adipo-
cytes, both in size and number and the relatively activated
macrophages may in turn produce cytokines that can modify
the functions of adipose cells and have significant impact on
metabolic processes in distant organs.8 In fact, animal data
show that increased inflammation in adipose tissue precedes
the development of obesity-induced insulin resistance.6
MIF is a widely expressed protein with potent proinflam-
matory action.27 In adipose cells the secretion of MIF
increases when MIF mRNA concentrations are relatively
constant throughout the differentiation process.26 The
release of MIF protein from human subcutaneous and
omental adipocytes positively correlate with the donors’
body mass index.26 In our study in Pima Indians, the
expression levels of MIF in preadipocytes positively corre-
lated with different measures of whole body and regional
obesity, whereas MIF expression in adipocytes correlated
only with the adipocyte size. This difference may be because
of the smaller number of subjects with data on adipocyte
MIF mRNA concentrations (type II error).
Increased concentrations of MIF in circulation have been
reported in subjects with T2DM and impaired glucose
tolerance.28,29 Higher MIF concentrations in circulation also
predicted increased risk of T2DM in Caucasian women.30
A previous study showed that Pima Indians, a population
with high propensities for obesity and T2DM, had higher
circulating MIF concentrations compared with Caucasians,
and MIF concentrations appeared to be increased in non-
diabetic Pima Indians with relatively impaired peripheral
insulin action.31 The lack of significant association between
plasma concentrations of MIF and measures of obesity or
Figure 1 Correlation of the mRNA concentrations of MIF in freshly isolated
adipocytes and cultured preadipocytes from subcutaneous abdominal adipose
tissue with mean adipocyte diameter. Symbols: close circlesFmale partici-
pants, open circlesFfemale participants.
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insulin action in our study may be explained by the rather
narrow range of adiposity and insulin sensitivity in our
subjects. In addition, our data indicate that adipocytes or
preadipocytes may not be a major source of MIF in the
circulation and that the association between MIF from
adipose cells and insulin action may be of an autocrine
and/or paracrine nature.
Studies in immune cells indicate several putative mecha-
nisms of autocrine/paracrine effects of MIF, including the
activation of extracellular signal-regulated kinase 1 (ERK1)/
ERK2Fmembers of the family of mitogen-activated protein
kinases (MAPKs), upregulation of toll like receptor 4 (TLR4)
or inhibition of p53 mediated apoptosis.27 ERK activation
in adipocytes inhibits secretion of the insulin-sensitizing
hormone adiponectin.32 In our study, the expression level of
MIF in adipocytes was negatively associated with plasma
adiponectin concentration. It could be speculated that local
MIF in adipose tissue may inhibit adiponectin secretion,
which in turn may result in impaired insulin action in
the skeletal muscle and the liver. However, this was not
supported by the multivariate model where MIF expression
but not circulating adiponectin was a significant predictor of
insulin action. Alternatively, MIF may activate TLR4, which
stimulates the activity of IkB/NF-kB pathway. Activation of
this proinflammatory pathway can affect insulin signaling
through increased release of proinflammatory cytokines.2
Conversely, genetic or immunologic inhibition of MIF in
mice prevented TNF-a-induced insulin resistance, whereas
recombinant MIF inhibited insulin signaling in adipocytes.33
Alternatively, elevated MIF expression in adipocytes may go
along with elevated MIF expression in other cell types, such
as resident macrophages within skeletal muscle or Kupfer
cells in the liver, thereby directly affecting peripheral and
hepatic insulin sensitivity. Embryonic fibroblasts from mice
with genetic MIF deficiency show increased expression of
proadipogenic genes.33 Increased adipogenic capacity of the
Figure 2 Spearman correlation between the expression levels of MIF gene in freshly isolated adipocytes or cultured preadipocytes from subcutaneous abdominal
adipose tissue and fasting plasma insulin, insulin-mediated glucose disposal (M) and endogenous glucose production (EGP) during the clamp. Symbols: close
circlesFmale participants, open circlesFfemale participants.
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precursor cells may lead to relatively more small, newly
differentiated adipocytes compared with older, lipid-laden
large fat cells.34 In fact, adipocyte size was inversely
associated with differentiation capacity of cultured preadi-
pocytes in a previous study from our group.35 Lower
proportion of newly differentiated adipocytes may also
explain reduced adiponectin production and secretion.36
However, it must be noted that knockdown of MIF gene
inhibited the differentiation and decreased expression of
adiponectin mRNA in murine 3T3-L1 preadipocytes,37 which
may represent species-specific differences. Adipocyte hyper-
trophy may also be a consequence of antiapoptotic action of
MIF through the p53 pathway.27 According to this scenario
adipocyte enlargement and insulin resistance may represent
two independent characteristics related to MIF overproduc-
tion from adipocytes.
Plasma glucose and insulin levels were positively asso-
ciated with the expression levels of MIF gene in adipo-
cytes and preadipocytes in our study. Past experiments in
3T3L1 adipocyte line have shown that the expression of
MIF could be stimulated by glucose and insulin, indicating
that increased expression of MIF may be a consequence of
metabolic dysregulation in obesity.38 However, this was not
confirmed in a recent study in isolated mature human
adipocytes.26 Furthermore, the association between plasma
glucose or insulin concentration and expression of MIF was
still present in the cultured preadipocytes, that is, cells that
underwent multiple division cycles after being separated
from the in vivo environment for at least 2 weeks. This
indicates that increased expression of MIF may represent an
intrinsic characteristic of adipose cell lineage of obese
individuals with relatively enlarged adipocytes and impaired
insulin action.
There are some potential caveats in interpreting the results
of this study. First, our study had an exploratory character
because of limited availability of biological material. There-
fore, we cannot exclude the possibility that some associa-
tions were significant by chance (type 1 error) as may be
indicated by multiple comparison tests (Supplementary
Table 2). However, consistent results of MIF expression
between two different cell types and laboratory settings,
that is, adipocytes and cultured preadipocytes, may counter-
act such an explanation. Inflammation-related genes can
also be expressed by macrophages in adipose tissue. Previous
experiment from our lab indicate that although macro-
phages may be present in the preadipocyte cultures, they
were not likely to be a major contaminant.13 Collagenase
digestion of adipose tissue during isolation could potentially
stimulate the transcription of inflammation-related genes in
adipocytes.39 Although this may have affected the gene
expression levels in our study, all our samples were subjected
to the same digestion procedure that likely affected all
samples similarly. Furthermore, among the measured genes
transcripts, the mRNA concentrations of MIF may be the
least affected by the digestion procedure because of its
constitutive expression pattern.27 We cannot exclude that
Figure 3 Spearman correlations between the expression levels of MIF gene in freshly isolated adipocytes or cultured preadipocytes from subcutaneous abdominal
adipose tissue and fasting serum MIF and plasma adiponectin concentrations. Symbols: close circlesFmale participants, open circlesFfemale participants.
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the average cell size might have been underestimated in
subjects with the largest fat cells due to their increased
propensity for disruption/lysis when treated by collagenase
but if anything, this would likely have led to an under-
estimation of the relationship between adipocyte size and
MIF expression.40 Also, it must be noted that hepatic insulin
action was overestimated in over 40% of the study group
with complete suppression of EGP due to both the insulin
dose used and the dilution effect of unlabeled glucose.41
Therefore, some caution is warranted when interpreting the
results on hepatic insulin sensitivity.
In conclusion, our data show that increased expression of
MIF gene in cells of adipocyte lineage is associated with
obesity characterized by enlarged subcutaneous abdominal
adipocytes, reduced circulatory adiponectin and impaired
insulin action on glucose uptake and production. Although
these results indicate a compelling role for this abundant
and potent proinflammatory cytokine in the development
of metabolic complications of obesity, further studies are
necessary to elucidate mechanisms underlying and the
clinical risks related to these associations.
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